申请人:Farmitalia Carlo Erba s.r.l.
公开号:US04826837A1
公开(公告)日:1989-05-02
The invention relates to compounds having the general formula (I) ##STR1## wherein n is zero, 1 or 2; each of R.sub.1 and R.sub.2 is independently: (a) hydrogen, halogen, trifluoromethyl or C.sub.1 -C.sub.6 alkyl; (b) hydroxy, C.sub.1 -C.sub.6 alkoxy or C.sub.3 -C.sub.4 alkenyloxy; (c) nitro, amino, formylamino or C.sub.2 -C.sub.8 alkanoylamino; R.sub.3 represents hydrogen or C.sub.1 -C.sub.8 alkyl; R.sub.4 is: (a') C.sub.1 -C.sub.20 alkyl, unsubstituted or substituted by ##STR2## wherein each of R.sub.a and R.sub.b is independently phenyl or C.sub.1 -C.sub.6 alkyl, or R.sub.a and R.sub.b, taken together with the nitrogen atom to which they are linked, form a N-pyrrolidinyl, N-piperazinyl, hexahydroazepin-1-yl, thiomorpholino, morpholino or piperidino ring, wherein said heterocyclic rings may be unsubstituted or substituted by C.sub.1 -C.sub.6 alkyl or phenyl; (b') C.sub.5 -C.sub.10 cycloalkyl, unsubstituted or substituted by methyl; (c') 2- or 3-pyrrolidinyl, piperidyl of 2-piperazinyl, wherein said heterocyclic rings may be unsubstituted or substituted by C.sub.1 -C.sub.6 alkyl; (d') isoxazolyl or thiazolyl, wherein said heterocyclic rings may be unsubstituted or substituted by C.sub.1 -C.sub.6 alkyl; (e') pyridyl, unsubstituted or substituted by one or two substituents chosen independently from halogen, C.sub.1 -C.sub.6 alkyl and C.sub.1 -C.sub.6 alkoxy; or (f') phenyl, unsubstituted or substituted by one or two substituents chosen independently from halogen, CF.sub.3,C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, amino, nitro, formylamino and C.sub.2 -C.sub.8 alkanoylamino, and the pharmaceutically acceptable salts thereof, which possess immunomodulating activity and are useful e.g. in the treatment of neoplastic diseases and acute and chronic infections of both bacterial and viral origin in mammals.
本发明涉及具有通式(I)的化合物 ##STR1## 其中n为0、1或2;每个R1和R2独立地为:(a)氢、卤素、三氟甲基或C1-C6烷基;(b)羟基、C1-C6烷氧基或C3-C4烯氧基;(c)硝基、氨基、甲酰氨基或C2-C8烷酰氨基;R3代表氢或C1-C8烷基;R4为:(a')C1-C20烷基,未被取代或被##STR2##取代,其中每个Ra和Rb独立地为苯基或C1-C6烷基,或者Ra和Rb与它们所连接的氮原子一起形成N-吡咯烷基、N-哌嗪基、六氢氮杂环庚三烯-1-基、硫代吗啉基、吗啉基或哌啶基环,其中所述杂环环可未被取代或被C1-C6烷基或苯基取代;(b')C5-C10环烷基,未被取代或被甲基取代;(c')2-或3-吡咯烷基、哌啶基或2-哌嗪基,其中所述杂环环可未被取代或被C1-C6烷基取代;(d')异噁唑基或噻唑基,其中所述杂环环可未被取代或被C1-C6烷基取代;(e')吡啶基,未被取代或被一个或两个独立地选自卤素、C1-C6烷基和C1-C6烷氧基的取代基取代;或(f')苯基,未被取代或被一个或两个独立地选自卤素、CF3、C1-C6烷基、C1-C6烷氧基、氨基、硝基、甲酰氨基和C2-C8烷酰氨基的取代基取代,以及其药学上可接受的盐,它们具有免疫调节活性,并且例如在治疗哺乳动物的肿瘤疾病以及由细菌和病毒引起的急性和慢性感染方面有用。